Outlook Therapeutics, Inc. OTLK was a big mover last session, as the company saw its shares rise 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company —as the stock is now up 84.5% in the past one-month time frame.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Outlook Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Outlook Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Oncobiologics, Inc. Price
Oncobiologics, Inc. price | Oncobiologics, Inc. Quote
A better-ranked stock in the Medical – Biomedical and Genetics industry is Akcea Therapeutics, Inc. AKCA, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
Oncobiologics, Inc. (OTLK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research